PAREXEL EXPERTS TO DISCUSS GLOBAL CAPABILITIES TO MEET URGENT DEMAND FOR CARDIOVASCULAR TREATMENTS AT AHA SCIENTIFIC SESSIONS
Boston, MA, November 16, 2009 –PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that experts from its global Cardiovascular/Metabolism Therapeutic Area Team will be available during the American Heart Association (AHA) Scientific Sessions 2009 to discuss how biopharmaceutical companies can more quickly bring safe and effective new treatments to market for patients who face cardiovascular diseases. Attendees can visit PAREXEL’s experts at Booth #2016 in the Science & Technology Hall during the AHA meeting, being held November 14 – 18, 2009 in Orlando, Florida.
According to the AHA, an estimated 80 million American adults (one in three) have one or more types of cardiovascular diseases (CVDs).* Additionally, the World Health Organization (WHO) reports that CVDs are the number one cause of death globally, and more people die annually from CVDs than from any other cause.
“With urgent demand growing for cardiovascular related treatments, PAREXEL is focused on leveraging our global footprint and regulatory and clinical experts worldwide to bring cost and time efficiencies to the development of innovative new drugs and devices in this area,” said Mark A. Goldberg, M.D., Chief Operating Officer. “Biopharmaceutical companies developing cardiovascular treatments not only rely on PAREXEL’s ability to access diverse patient populations, navigate regulatory issues, and identify effective investigators but also to provide insightful strategic guidance in study design and execution.”
Over the past five years, PAREXEL has conducted hundreds of clinical trials for a broad range of cardiovascular and metabolic related indications, including acute coronary symptoms, coronary artery disease, peripheral arterial disease/thrombosis, pulmonary hypertension, venous disease, arrhythmia, diabetes, arterial hypertension, dyslipidemia/obesity, and heart failure. PAREXEL’s therapeutic area team, including cardiologists and endocrinologists who provide understanding of the underlying mechanisms and complex nature of diseases in this area, guide clinical development through every stage.
According to Thomas Shook, M.D., Vice President, Worldwide Medical Affairs, PAREXEL, “In the cardiology area in particular, compounds require extremely large international studies in the late phase to obtain results with meaningful statistical significance. Our global team of experts helps clients address this challenge by applying proven experience in conducting mega-trials, involving thousands of clinical sites and tens of thousands of patients, and the ability to centrally assess and adjudicate clinical end-points.”
PAREXEL’s Cardiology/Endocrinology Therapeutic Area Team offers expertise to help clients with every facet of clinical development, including protocol review, safety assessment, medical imaging, technology integration, regulatory affairs, and product lifecycle management. Comprehensive services provided by the team include the planning, design, and management of feasibility studies, Phase I – IV trials, and post-marketing studies as well as site selection, patient recruitment, data analysis, non-clinical evaluation, and IND/NDA submissions. PAREXEL leverages the experience and relationships its experts have with leading academic research centers and key opinion leaders in its ongoing collaborative efforts. PAREXEL applies a proven, therapeutically focused expertise methodology to clinical development programs across a broad range of areas. For more information about PAREXEL’s in-depth expertise in cardiology, as well as oncology, neurology, infectious disease, and a broad range of other therapeutic areas, visit: http://www.PAREXEL.com/clinical_research/therapeutic_expertise.html.
Information about the AHA Scientific Sessions can be found at: http://scientificsessions.americanheart.org.
# # #
* Heart Disease and Stroke Statistics — 2009 Update, American Heart Association
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has more than 9,130 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 as filed with the SEC on November 6, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.